| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Departments of Oral Biology and Microbiology, Immunobiology Vaccine Center, University of Alabama, Birmingham, AL 35294;
California Regional Primate Research Center, Department of Pathology, School of Medicine, University of California, Davis, CA 95616;
AIDS Research Center, National Institute of Infectious Diseases,
Jissen Women’s College, and
¶ Division of Mucosal Immunology, Department of Microbiology and Immunology, Institute for Medical Sciences, University of Tokyo, Tokyo, Japan
The development of a safe and effective mucosal adjuvant is a crucial step toward a mucosal HIV/AIDS vaccine. This study seeks to determine the promise of a nontoxic mutant of cholera toxin (mCT; E112K) as a mucosal adjuvant in nonhuman primates. HIV-1 gp120 was nasally administered together with mCT E112K or native CT (nCT) as adjuvant on five to six occasions over a 6- to 8-wk period to groups of four rhesus macaques and alone to two monkeys that acted as controls. Macaques given nasal gp120 with either mCT E112K or nCT showed elevated gp120-specific IgG and IgA Ab responses with virus-neutralizing activity in both their plasma and mucosal external secretions, as well as higher numbers of gp120-specific IgA Ab-forming cells in their mucosal and peripheral lymphoid tissues and of IL-4-producing Th2-type CD4-positive (CD4+) T cells than did controls. Even though significant mucosal adjuvanticity was seen with both mCT E112K and nCT, neuronal damage was observed only in the nCT-treated, but not in the control or mCT E112K-treated groups. These results clearly show that mCT E112K is an effective and safe mucosal adjuvant for the development of a nasal HIV/AIDS vaccine.
This article has been cited by other articles:
|
|
 |
|
  F.X. Lu and R.S. Jacobson Oral Mucosal Immunity and HIV/SIV Infection Journal of Dental Research, March 1, 2007; 86(3): 216 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Hagiwara, Y. I. Kawamura, K. Kataoka, B. Rahima, R. J. Jackson, K. Komase, T. Dohi, P. N. Boyaka, Y. Takeda, H. Kiyono, et al. A Second Generation of Double Mutant Cholera Toxin Adjuvants: Enhanced Immunity without Intracellular Trafficking. J. Immunol., September 1, 2006; 177(5): 3045 - 3054. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kobayashi, T. Kohda, K. Kataoka, H. Ihara, S. Kozaki, D. W. Pascual, H. F. Staats, H. Kiyono, J. R. McGhee, and K. Fujihashi A Novel Neurotoxoid Vaccine Prevents Mucosal Botulism J. Immunol., February 15, 2005; 174(4): 2190 - 2195. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
